MND1

Summary

MND1 (meiotic nuclear divisions 1, HGNC:24839) is a protein-coding gene on chromosome 4q31.3, encoding Meiotic nuclear division protein 1 homolog (Q9BWT6). Required for proper homologous chromosome pairing and efficient cross-over and intragenic recombination during meiosis.

The product of the MND1 gene associates with HOP2 (MIM 608665) to form a stable heterodimeric complex that binds DNA and stimulates the recombinase activity of RAD51 (MIM 179617) and DMC1 (MIM 602721) (Chi et al., 2007 [PubMed 17639080]). Both the MND1 and HOP2 genes are indispensable for meiotic recombination.

Source: NCBI Gene 84057 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 55 total — 1 likely-pathogenic
• MANE Select transcript: NM_032117

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24839
Approved symbol	MND1
Name	meiotic nuclear divisions 1
Location	4q31.3
Locus type	gene with protein product
Status	Approved
Aliases	GAJ
Ensembl gene	ENSG00000121211
Ensembl biotype	protein_coding
OMIM	611422
Entrez	84057

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 12 protein_coding, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000240488, ENST00000503967, ENST00000504860, ENST00000508731, ENST00000509752, ENST00000622785, ENST00000902388, ENST00000940506, ENST00000940507, ENST00000940508, ENST00000940509, ENST00000940510, ENST00000940511, ENST00000940512

RefSeq mRNA: 2 — MANE Select: NM_032117 NM_001253861, NM_032117

CCDS: CCDS3782, CCDS75202

Canonical transcript exons

ENST00000240488 — 8 exons

Exon	Start	End
ENSE00000927449	153355654	153355711
ENSE00000927450	153358474	153358622
ENSE00001287969	153414751	153415118
ENSE00003485440	153408971	153409015
ENSE00003503854	153397219	153397333
ENSE00003553185	153350064	153350129
ENSE00003791411	153394262	153394336
ENSE00003890484	153344688	153344740

Expression profiles

Bgee: expression breadth ubiquitous, 132 present calls, max score 93.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.4587 / max 177.2784, expressed in 1159 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
50069	6.1461	1082
50068	1.3126	669

Top tissues by expression

136 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.48	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.03	gold quality
ventricular zone	UBERON:0003053	89.10	gold quality
ganglionic eminence	UBERON:0004023	86.76	gold quality
right testis	UBERON:0004534	83.47	gold quality
testis	UBERON:0000473	82.91	gold quality
left testis	UBERON:0004533	82.00	gold quality
mucosa of transverse colon	UBERON:0004991	76.59	gold quality
rectum	UBERON:0001052	76.20	gold quality
lymph node	UBERON:0000029	76.16	gold quality
bone marrow	UBERON:0002371	75.47	gold quality
placenta	UBERON:0001987	74.40	gold quality
vermiform appendix	UBERON:0001154	74.18	gold quality
endometrium	UBERON:0001295	73.52	gold quality
adrenal tissue	UBERON:0018303	72.09	gold quality
esophagus mucosa	UBERON:0002469	71.06	gold quality
duodenum	UBERON:0002114	70.02	gold quality
stromal cell of endometrium	CL:0002255	69.73	gold quality
lower esophagus mucosa	UBERON:0035834	69.49	gold quality
popliteal artery	UBERON:0002250	68.41	gold quality
tibial artery	UBERON:0007610	68.40	gold quality
bone marrow cell	CL:0002092	67.63	silver quality
smooth muscle tissue	UBERON:0001135	67.59	gold quality
spleen	UBERON:0002106	63.85	gold quality
transverse colon	UBERON:0001157	63.52	gold quality
gall bladder	UBERON:0002110	62.85	gold quality
hindlimb stylopod muscle	UBERON:0004252	62.47	gold quality
islet of Langerhans	UBERON:0000006	62.21	gold quality
esophagus	UBERON:0001043	62.07	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	61.73	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.64

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting MND1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-1290	99.59	69.90	2079
HSA-MIR-20A-3P	99.44	69.10	1575
HSA-MIR-6739-3P	99.22	68.84	1843
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-7151-3P	99.04	69.72	2370
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-197-3P	98.09	69.23	1004
HSA-MIR-676-3P	97.86	65.70	668
HSA-MIR-4793-5P	96.88	65.90	872
HSA-MIR-2355-3P	96.84	68.54	909
HSA-MIR-6782-5P	96.45	64.42	612

Literature-anchored findings (GeneRIF, showing 6)

• Data suggest that the human TBPIP/Hop2-Mnd1 complex may ensure proper pairing between homologous chromosomes through its stimulation of strand exchange during meiosis. (PMID:16407260)
• Data indicate that the positive expression of studied genes fertilization rate for GAPDHS positive subset was 66%, ACR - 71%, SPATA22 - 68%, MND1 - 70%, pregnancy rates were 8%, 6%, 18% and 36% respectively. (PMID:23675907)
• Assuming the mouse model accurately reflects the impact of this variant in humans, rs140107488 appears to be a benign allele that can be eliminated or de-prioritized in clinical genomic analyses of infertility patients. (PMID:31393579)
• Meiotic nuclear divisions 1 (MND1) fuels cell cycle progression by activating a KLF6/E2F1 positive feedback loop in lung adenocarcinoma. (PMID:33734616)
• Genetic network and gene set enrichment analyses identify MND1 as potential diagnostic and therapeutic target gene for lung adenocarcinoma. (PMID:33941804)
• MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma. (PMID:36098680)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mnd1	ENSDARG00000074451
mus_musculus	Mnd1	ENSMUSG00000033752
rattus_norvegicus	Mnd1	ENSRNOG00000024733

Protein

Protein identifiers

Meiotic nuclear division protein 1 homolog — Q9BWT6 (reviewed: Q9BWT6)

All UniProt accessions (5): A0A087WTC6, D6R9E3, D6RCT6, D6RIA0, Q9BWT6

UniProt curated annotations — full annotation on UniProt →

Function. Required for proper homologous chromosome pairing and efficient cross-over and intragenic recombination during meiosis. Stimulates both DMC1- and RAD51-mediated homologous strand assimilation, which is required for the resolution of meiotic double-strand breaks.

Subunit / interactions. Heterodimer with PSMC3IP/HOP2. MND1-PSMC3IP interacts with DMC1 and RAD51 and binds preferentially to dsDNA.

Subcellular location. Nucleus.

Similarity. Belongs to the MND1 family.

RefSeq proteins (2): NP_001240790, NP_115493* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005647	Mnd1	Family
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR040453	Mnd1_HTH	Domain
IPR040661	LZ3wCH	Domain

Pfam: PF03962, PF18517

UniProt features (4 total): initiator methionine 1, chain 1, coiled-coil region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BWT6-F1	91.23	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-912446	Meiotic recombination
R-HSA-1474165	Reproduction
R-HSA-1500620	Meiosis
R-HSA-1640170	Cell Cycle

MSigDB gene sets: 161 (showing top): GOBP_MEIOTIC_CHROMOSOME_SEGREGATION, REACTOME_MEIOTIC_RECOMBINATION, GOBP_CHROMOSOME_ORGANIZATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, RACCACAR_AML_Q6, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_ORGANELLE_FISSION, GATA6_01, GOBP_CHROMOSOME_ORGANIZATION_INVOLVED_IN_MEIOTIC_CELL_CYCLE, DODD_NASOPHARYNGEAL_CARCINOMA_UP, FISCHER_DREAM_TARGETS, GOBP_HOMOLOGOUS_CHROMOSOME_SEGREGATION, GOBP_MEIOTIC_CELL_CYCLE_PROCESS, GOBP_HOMOLOGOUS_CHROMOSOME_PAIRING_AT_MEIOSIS

GO Biological Process (4): homologous chromosome pairing at meiosis (GO:0007129), reciprocal meiotic recombination (GO:0007131), DNA recombination (GO:0006310), meiotic cell cycle (GO:0051321)

GO Molecular Function (3): double-stranded DNA binding (GO:0003690), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Meiosis	1
Reproduction	1
Cell Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
homologous chromosome segregation	1
chromosome organization involved in meiotic cell cycle	1
meiosis I	1
reciprocal homologous recombination	1
meiotic cell cycle process	1
DNA metabolic process	1
cell cycle	1
sexual reproduction	1
reproductive process	1
meiotic nuclear division	1
DNA binding	1
nucleic acid binding	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1206 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MND1	RAD51	Q06609	968
MND1	PSMC3IP	Q9P2W1	962
MND1	SPO11	Q9Y5K1	810
MND1	MSH5	O43196	798
MND1	MSH4	O15457	796
MND1	HFM1	A2PYH4	772
MND1	RAD52	P43351	769
MND1	RAD51C	O43502	745
MND1	SWI5	Q1ZZU3	735
MND1	BRCA2	P51587	725
MND1	REC8	O95072	722
MND1	ATRX	P46100	718
MND1	XRCC3	O43542	696
MND1	BMP7	P18075	694
MND1	EXO1	Q9UQ84	691

IntAct

15 interactions, top by confidence:

A	B	Type	Score
PSMC3IP	MND1	psi-mi:“MI:0407”(direct interaction)	0.900
ALOX5	DDHD2	psi-mi:“MI:0914”(association)	0.530
MND1	PDIA3	psi-mi:“MI:0915”(physical association)	0.400
MND1	IK	psi-mi:“MI:0914”(association)	0.350
MND1	SPAG9	psi-mi:“MI:0914”(association)	0.350
PSMC3IP	CCNB1	psi-mi:“MI:0914”(association)	0.350
EIF1AD	CHEK1	psi-mi:“MI:0914”(association)	0.350
MND1	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
MND1		psi-mi:“MI:0914”(association)	0.350
KRAS		psi-mi:“MI:0914”(association)	0.350

BioGRID (58): PSMC3IP (Co-fractionation), IK (Affinity Capture-MS), PSMC3IP (Affinity Capture-MS), PSMC3IP (Affinity Capture-MS), MTERF4 (Affinity Capture-MS), NSUN4 (Affinity Capture-MS), MND1 (Affinity Capture-MS), SPAG9 (Affinity Capture-MS), MND1 (Co-purification), RAD51 (Far Western), MND1 (Proximity Label-MS), MND1 (Affinity Capture-MS), PSMC3IP (Affinity Capture-MS), MND1 (Affinity Capture-MS), NSUN4 (Affinity Capture-MS)

ESM2 similar proteins: A2YDY2, A4FUH0, G1TG89, G1TSG1, P35268, P42794, P42798, P47198, P48597, P50886, P50894, P52865, P62084, P62244, P62245, P62246, P62495, P62496, P62497, P62498, P67984, P67985, P86048, Q0DK10, Q0VCX5, Q28IL6, Q32L19, Q4R4D3, Q4R5I3, Q5I0R6, Q5NVP9, Q5R4C7, Q5R938, Q5U2Q7, Q6AYU1, Q6P5R6, Q6Q420, Q76I82, Q8BWY3, Q8CJ19

Diamond homologs: Q09739, Q32L19, Q54E86, Q5XGY9, Q6DC61, Q8GYD2, Q8K396, Q9BWT6, P53102

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	33
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
812128	GRCh37/hg19 4q31.3(chr4:154316483-154325120)	Likely pathogenic

SpliceAI

1452 predictions. Top by Δscore:

Variant	Effect	Δscore
4:153350062:A:AG	acceptor_gain	1.0000
4:153350063:G:GC	acceptor_gain	1.0000
4:153350063:GTC:G	acceptor_gain	1.0000
4:153350127:ACA:A	donor_gain	1.0000
4:153350127:ACAG:A	donor_loss	1.0000
4:153350128:CA:C	donor_gain	1.0000
4:153350128:CAG:C	donor_loss	1.0000
4:153350129:AG:A	donor_loss	1.0000
4:153350130:G:GG	donor_gain	1.0000
4:153350130:GTAAG:G	donor_loss	1.0000
4:153350131:TA:T	donor_loss	1.0000
4:153350132:AA:A	donor_loss	1.0000
4:153355639:A:G	acceptor_gain	1.0000
4:153358472:A:AG	acceptor_gain	1.0000
4:153358473:G:GG	acceptor_gain	1.0000
4:153358473:GCT:G	acceptor_gain	1.0000
4:153397190:A:AG	acceptor_gain	1.0000
4:153397193:T:A	acceptor_gain	1.0000
4:153397200:A:AG	acceptor_gain	1.0000
4:153397334:G:GG	donor_gain	1.0000
4:153344738:ATGGT:A	donor_loss	0.9900
4:153344741:G:A	donor_loss	0.9900
4:153344741:G:GG	donor_gain	0.9900
4:153344742:TAA:T	donor_loss	0.9900
4:153350060:TTAGT:T	acceptor_loss	0.9900
4:153350061:TAGT:T	acceptor_loss	0.9900
4:153350062:A:AC	acceptor_loss	0.9900
4:153350063:G:A	acceptor_loss	0.9900
4:153350063:GT:G	acceptor_gain	0.9900
4:153350063:GTCA:G	acceptor_gain	0.9900

AlphaMissense

1366 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:153355691:C:A	A36D	0.987
4:153355663:T:C	F27L	0.982
4:153355665:T:A	F27L	0.982
4:153355665:T:G	F27L	0.982
4:153358543:G:A	G66E	0.981
4:153409009:T:A	W169R	0.980
4:153409009:T:C	W169R	0.980
4:153358525:T:A	V60D	0.977
4:153355673:A:T	K30I	0.975
4:153358566:T:C	F74L	0.974
4:153358568:T:A	F74L	0.974
4:153358568:T:G	F74L	0.974
4:153358489:A:T	K48I	0.971
4:153350096:G:C	K12N	0.970
4:153350096:G:T	K12N	0.970
4:153355674:A:C	K30N	0.968
4:153355674:A:T	K30N	0.968
4:153358538:G:C	R64S	0.967
4:153358538:G:T	R64S	0.967
4:153358560:T:A	W72R	0.966
4:153358560:T:C	W72R	0.966
4:153408997:G:C	A165P	0.965
4:153358490:A:C	K48N	0.964
4:153358490:A:T	K48N	0.964
4:153358557:T:G	Y71D	0.964
4:153358562:G:C	W72C	0.964
4:153358562:G:T	W72C	0.964
4:153355709:T:C	I42T	0.959
4:153414755:C:A	N172K	0.952
4:153414755:C:G	N172K	0.952

dbSNP variants (sampled 300 via entrez): RS1000093954 (4:153355262 A>T), RS1000122276 (4:153395824 A>G), RS10001605 (4:153386316 A>C,T), RS1000193485 (4:153391469 T>C), RS1000219142 (4:153373737 C>A,T), RS1000226286 (4:153391291 G>T), RS1000236399 (4:153371703 A>G), RS1000425220 (4:153397738 C>A,T), RS1000454935 (4:153414421 A>G), RS1000480267 (4:153385239 T>C), RS1000481540 (4:153342717 C>T), RS1000499328 (4:153373129 T>G), RS1000597938 (4:153380148 A>G,T), RS1000699564 (4:153365098 C>T), RS10007316 (4:153363504 A>C,G,T)

Disease associations

OMIM: gene MIM:611422 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

59 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	4
Benzo(a)pyrene	decreases expression, increases expression	3
Tetrachlorodibenzodioxin	affects expression, decreases expression	3
Tretinoin	decreases expression	3
Valproic Acid	decreases expression	3
Cadmium Chloride	increases abundance, decreases expression	3
trichostatin A	affects cotreatment, decreases expression	2
Acetaminophen	decreases expression, increases expression	2
Arsenic	affects cotreatment, increases abundance, increases expression, decreases expression	2
Estradiol	increases expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Rotenone	decreases expression, increases expression	2
Cyclosporine	decreases expression, increases expression	2
dicrotophos	decreases expression	1
lasiocarpine	increases expression	1
propionaldehyde	decreases expression	1
bisphenol A	decreases expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
beta-methylcholine	affects expression	1
avobenzone	increases expression	1
phenethyl isothiocyanate	decreases expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
CGP 52608	affects binding, increases reaction	1
deguelin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
pyrachlostrobin	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E2CM	HAP1 MND1 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists